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Translational Relevance: This research using samples from ovarian cancer patients 
shows that three to four cycles of platinum-based chemotherapy alters the functional 
orientation, activation status and density of certain T cell subsets in a tumor 
microenvironment and reduces systemic levels of tumor promoting cytokines. The 
results suggest that the effects of immunotherapy might be enhanced if given after 
chemotherapy, potentially improving disease control in patients with advanced HGSC 
and other cancer types.  
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Abstract  
Purpose 
The purpose of this study was to assess the effect of neoadjuvant chemotherapy, 
NACT, on immune activation in stage IIIC/IV tubo-ovarian high-grade serous carcinoma 
(HGSC), and its relationship to treatment response. 
 
Experimental Design 
We obtained pre- and post-treatment omental biopsies and blood samples from a total 
of fifty-four patients undergoing platinum-based NACT and six patients undergoing 
primary debulking surgery. We measured T cell density and phenotype, immune 
activation and markers of cancer-related inflammation using immunohistochemistry, 
flow cytometry, electrochemiluminescence assays and RNA sequencing and related our 
findings to histopathological treatment response. 
 
Results 
There was evidence of T cell activation in omental biopsies after NACT: CD4+ T cells 
showed enhanced IFNγ production and anti-tumor Th1 gene signatures were increased. 
T cell activation was more pronounced with good response to NACT. The CD8+ T cell 
and CD45RO+ memory cell density in the tumor microenvironment was unchanged after 
NACT but biopsies showing a good therapeutic response had significantly fewer FoxP3+ 
T regulatory cells. This finding was supported by a reduction in a T regulatory cell gene 
signature in post versus pre NACT samples that was more pronounced in good 
responders. Plasma levels of pro-inflammatory cytokines decreased in all patients after 
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NACT. However, a high proportion of T cells in biopsies expressed immune checkpoint 
molecules PD-1 and CTLA4, and PD-L1 levels were significantly increased after NACT.  
 
Conclusions 
NACT may enhance host immune response but this effect is tempered by 
high/increased levels of PD-1, CTLA4 and PD-L1. Sequential chemo-immunotherapy 
may improve disease control in advanced HGSC.  
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Introduction 
The aim of this study was to determine the influence of neoadjuvant chemotherapy, 
NACT, on the immune microenvironment in peritoneal metastases of high-grade serous 
ovarian cancer, HGSC. Early peritoneal and pleural spread is a feature of HGSC with a 
majority of patients presenting with FIGO stage IIIC and stage IV disease (1).  
Platinum-based chemotherapy is the only backbone medical first line treatment 
approved for HGSC in the past thirty years and although most patients respond initially, 
resistance eventually develops in a majority of them. Peritoneal metastases are 
frequently the site of relapse and eventually lead to bowel obstruction that contributes to 
death in many patients (2,3). 
In patients with Stage IIIC or IV disease who are not suitable for primary debulking 
surgery (PDS), three cycles of platinum-based NACT followed by interval debulking 
surgery (IDS) and adjuvant chemotherapy is an accepted alternative approach. This is 
equally effective while potentially associated with lower morbidity (4,5) although there is 
a need for international consensus criteria for patient selection in this approach. 
There is good evidence that HGSC has potential to be an immunogenic tumor and 
activated T cells have been characterized in the tumor microenvironment and ascitic 
fluid (6) (7). There is an association between increased tumor-infiltrating leukocyte, TIL, 
density and longer survival (8,9) and TIL sub populations recognize shared tumor 
antigens, gene products from somatic mutations, as well as amplified or aberrant genes 
(10,11). Mutation frequency also correlated with an immune cell cytolytic activity 
transcriptional signature in ovarian cancer databases (12). However, TIL in HGSC 
biopsies are often suppressed or functionally exhausted, and immunotherapies, until 
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recently, not yet had a major impact on patients with advanced chemo-resistant disease 
(10,11,13).  
Recent studies in animal cancer models have shown how the immune system plays an 
important role in the response to some cancer chemotherapies, inducing an 
‘immunogenic’ cell death, presentation of neoantigens and an increase in acute 
inflammatory and tumor-destructive responses (14-16). Furthermore, recent mouse 
cancer experiments showed the efficacy of blocking the PD-1/PD-L1 axis following 
paclitaxel chemotherapy (17). The ability to sample HGSC biopsies at diagnosis and 
after NACT during surgery, gives us an opportunity to ask if similar responses occur in a 
clinical setting and if they do, whether this provides a rationale for introducing 
immunotherapy after NACT rather than in relapsed disease. We therefore studied a 
cohort of fifty-four women with stage IIIC and stage IV HGSC receiving NACT, as well 
as six women who underwent surgery before chemotherapy. Using transcriptional and 
protein analyses of prospectively collected metastatic peritoneal (omental) specimens, 
as well as plasma samples, we investigated the effects of platinum-based NACT on the 
immune microenvironment in patients and compared this to their response to 
chemotherapy as assessed by a recently published prognostic histologic score (18).   
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Materials and Methods 
Patients and samples 
Institutional review board approval was granted for the Barts Gynae Tissue Bank to 
collect and store biological material and clinical information. Patients were treated at St 
Bartholomew’s Cancer Centre between 2010 and 2015 and gave written informed 
consent. Clinical parameters were collected using tissue repository databases and chart 
review.  
Omental metastases and plasma samples from fifty-four FIGO stage IIIC and IV HGSC 
patients were collected prospectively before and after platinum-based neoadjuvant 
chemotherapy (details of patients and treatment are shown in Supplementary Table 1) 
and analysed in immunohistochemical, flow cytometric and transcriptomic experiments. 
Surgery was usually performed between three and four weeks after the last NACT. 
Samples from an additional six patients with FIGO stage IIIC and IV HGSC who 
underwent primary debulking surgery were used in the flow cytometry and RNAseq 
studies described below (Supplementary Table 2). These samples were matched to the 
NACT cohort in terms of amount of tumor and stroma in the biopsy, pre-treatment levels 
of plasma cytokines, age and stage. Inflammatory cytokine levels were measured in 
paired pre and post NACT plasma samples of twenty-three patients and twenty-two 
plasma samples were from healthy female volunteers (median age 47.5y, range 32 - 
64). Supplementary Table 3 lists the numbers of samples that were used in each of the 
analyses.  
The response to chemotherapy was assessed in IDS biopsies using a chemotherapy 
response score (CRS) that separates the patients into three major subgroups (18). 
CRS1 samples show minimal response to chemotherapy, CRS2,‘poor’ responders, 
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have easily identifiable malignant cells in the omentum after NACT and CRS3, ‘good’ 
responders, usually show extensive regression-associated fibro-inflammatory changes 
with absent or minimal numbers of malignant cells (18).  
Formalin-fixed paraffin embedded (FFPE) tumor biopsies 
Pre-treatment omental or peritoneal biopsies were obtained at diagnostic laparoscopy 
or diagnostic core biopsy. Sections of 4µm thickness were mounted on glass slides. 
Blocks of omentum removed at interval debulking surgery after neoadjuvant 
chemotherapy, were reviewed by a pathologist according to ICCR guidelines (19). 
Blocks representing the area of worst response were selected and used to construct 
tissue microarrays (TMA) with a 1mm core size and up to 6 cores per patient sample.  
Fresh tumor biopsies 
Omental biopsies were collected in the operating theatre from untreated patients 
undergoing primary debulking surgery, PDS or diagnostic laparoscopy and from 
patients undergoing interval debulking surgery after NACT and fresh-frozen samples 
were histologically matched to FFPE specimens of the same patient by H&E review.  
Blood samples 
Sodium heparin blood (BD Vacutainer Systems) was immediately placed on ice within 
one week before NACT and within two weeks before IDS. The minimum time after the 
last cycle of chemotherapy was three weeks. Following centrifugation plasma from 
patients and controls was snap frozen and stored at -80°C.  
Extraction of stroma vascular fraction  
Fresh omental biopsies were subjected to mechanical dissection and enzymatic 
treatment. Briefly, the tissue was dissected with a scalpel, incubated in RPMI medium 
(Gibco) containing 5% FBS, 1mg/ml Collagenase D from clostridium histolyticum 
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(Roche) and 25µg/ml DNAse (Roche) at 37°C under agitation for 40min. The extract 
was then filtered through a 70µm pore strainer; red blood cells were lysed (eBioscience) 
and the Stroma Vascular Fraction (SVF) was frozen for later FACS analyses or freshly 
re-stimulated in vitro for intra-cellular cytokine staining. 
Flow cytometry analyses 
SVFs and peripheral blood mononuclear cells (PBMCs) were stained for flow cytometry 
analyses in PBS containing 2.5% BSA and 2mM EDTA for 30min at 4˚C. The following 
markers were used: CD45 APC efluor780 (eBioscience), CD3 BV650 (Biolegend), CD3 
PE (eBioscience), CD4 PerCP-Cy5.5 (eBioscience), CD8 APC (eBioscience), CD8 
FITC (eBioscience), PD-1 BV421 (Biolegend), CTLA4 PE (Biolegend), CD69 APC 
(eBioscience), CD25 PECy7 (eBioscience). Viability of the cells was assessed by 
staining with the fixable viability dye (FVD) eFluor506 (eBioscience) or DAPI (Sigma). 
Appropriate Fluorescence Minus One (FMO) controls were used in these experiments. 
Staining for Foxp3+ T regulatory cells was performed using the Human Treg Kit 
(eBioscience) containing CD45 eFluor 780, CD4 FITC/CD25 APC, FOXP3 PE and the 
isotype control for Foxp3. Viability of the cells was assessed with FVD eFluor450 
(eBioscience).  
To study the production of IL-10 and IFNγ by omental T cells from pre and post 
treatment patients, 2.5 106 cells from the extracted SVF were re-stimulated in vitro in 
RPMI 10% FBS, 50ng/mL phorbol 12-myristate 13-acetate (PMA) (Sigma) and 1µg/mL 
Ionomycin (Sigma) for 5h at 37˚C, 5% CO2. After the first hour of re-stimulation 10µg/ml 
Brefeldin A (Sigma) were added to the culture. Following re-stimulation, cells were 
stained for CD4 PerCP-Cy5.5 (eBioscience), CD8 FITC (eBioscience) and FVD 450 
(eBioscience) in PBS 2.5% BSA + 2mM EDTA for 20min at 4˚C. Cells were then 
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washed, fixed for 20min at room temperature with the Fixation Buffer (eBioscience), 
permeabilized with the Permeabilization Buffer (eBioscience) and stained with anti-
human IL10 PE (eBioscience) and IFNγ PECy7 (eBioscience) for 20min at room 
temperature. Corresponding isotype controls for IL10 and IFNγ were used to generate 
FMO controls. Stained samples were analysed using a LSRFortessa cell analyser (BD 
Biosciences) and data were analysed with FlowJo 9.4.6 (Treestar Inc.).  
Immunohistochemistry 
FFPE-embedded tissue sections were dewaxed and rehydrated. Antigen retrieval was 
performed using a pressure cooker and a citrate based antigen unmasking solution 
(Vector Laboratories) followed by staining in an autostainer (Dako) using an 
ultrasensitive HRP Polymer Kit (Biogenex). The following antibodies were used: CD8 
clone C8/144B (Dako), FOXP3 clone 236A/E7 (abcam), CD45RO clone UCLH (Dako), 
PD-L1 clone SP142 (Spring Bioscience/Roche). Negative controls were isotype 
matched. 
Immune cell quantification on digitalized slides 
Immunohistochemically stained slides were scanned at 20x with a Pannoramic Flash 
Scanner (3D Histech). Images of 5 areas representing the entire biopsy of paired pre-
post NACT samples were taken with an area of 0.58mm2 per high-power field 
(Pannoramic software, 3D Histech).  Intra-epithelial cells (within tumor islets) and intra-
stromal cells were counted independently by three investigators, including one 
histopathologist, blinded for clinical information. Each HPF was scored as 0, 1+, 2+, 3+ 
or 4+ for tumor (within or direct contact with the epithelial component) and stromal 
regions. The cut-off was based on the typical density of these cell populations in HGSC 
omentum and prior joint discussion of the investigators (CD8 and CD45RO: no cells, 1-
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10, 11-60, 61-150, >150 per HPF, respectively. FOXP3: no cells, 1-10, 11-40, 41-100, 
>100 per HPF respectively). The average score of all HPFs of one slide of one 
investigator was added to the corresponding scores of the other two and then divided by 
three.  
Scoring of PD-L1 expression  
PD-L1 was scored by a study pathologist using the criteria described in (20). Briefly, 
samples were scored for PD-L1 expression on tumor-infiltrating immune cells, which 
included macrophages, dendritic cells and lymphocytes. Specimens were given a score 
of 0-3 if <1%, 1-<5%, 5-<10% and ≥10% of cells were positive for PD-L1.  
Plasma cytokine analysis 
Cytokines were measured by electrochemiluminescence multiplex assay (V-Plex, MSD) 
on a Sector Imager (MSD) according to the manufacturers’ protocol. The detection 
range for the assays was as follows: TNFα: 0.076pg/ml to 311 pg/ml; IL8: 0.133 pg/ml 
to 546pg/ml; IL6: 0.369pg/ml to 749pg/ml; IFNγ: 0.369pg/ml to 1510pg/ml; IL10: 
0.076pg/ml to 313pg/ml; IL17: 1.38pg/ml to 5670pg/ml. 
 
RNA isolation 
Total RNA was isolated from frozen whole tissue using the RNeasy kit (Qiagen) 
following the manufacturers’ instructions. Briefly, whole tissue was homogenized in RLT 
lysis buffer, passed through a QIAshredder (Qiagen) then purified on the mini spin 
columns, including the on-column DNAse treatment to remove any remaining DNA. The 
purified total RNA was then analyzed by Bioanalyzer 2100 expert (Agilent) as per 
manufacturers’ instructions. RIN numbers between 9.9 and 8.0 were obtained.    
Transcriptomic analysis 
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RNA Sequencing was performed by Oxford Gene Technology (Begbroke UK) using the 
Illumina HiSeq2500 platform and generated ~42 million 101 Base-pair paired end reads 
per sample. Sequenced reads were mapped to Human RefSeq genes archived in the 
Illumina iGenomes resource 
(http://support.illumina.com/sequencing/sequencing_software/igenome.html)  
using RSEM (21)(version 1.2.4) in dUTP strand-specific mode. As part of the RSEM 
pipeline, bowtie (version 0.12.7) (22) was used to perform the mapping 
stage.  Subsequent mapped read counting was performed using RSEM.  Differentially 
expressed genes were identified with the EdgeR package (23) using Bioconductor 
(version 2.7; www.bioconductor.org), running on R (version 2.12.1;R-REF). Genes with 
logCPM > 0 and FDR <0.05 were judged to be differentially expressed. Immunologic 
signatures that represent cell states and perturbations within the immune system were 
extracted from Msigdb (24) and used to perform GSEA with default settings comparing 
pair-wise comparisons. GSEA analysis on pre and post NACT samples, were 
interrogated using the MSigDB C7 immunologic collection available from the Broad 
Institute. This consisted of 1910 signatures, which comprise approximately 200 genes 
per signature. Signatures were considered significant if the corrected FDR q value was 
<0.05. Heatmaps shown in figures 3 and 4 are truncated to show only the genes 
identified as contributing to the enrichment score.  
Data and materials availability 
FASTQ data files supporting the RNASeq analysis have been uploaded to NCBI GEO 
database GSE71340. 
Statistical analysis 
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For continuous variables that were approximately normally or normally distributed, 
mean and standard error of the mean are shown and t-test was conducted. For ordinal 
variables Mann Whitney test or Wilcoxon matched-pairs signed rank test were applied 
and Kruskal-Wallis test was used in addition to perform multiple group comparisons. 
Progression-free survival (PFS) was calculated from the date of first neoadjuvant 
chemotherapy to progression or death (whichever came first) using GCIG CA-125 
criteria for biochemical progression. Overall survival (OS) was calculated from the date 
of first neoadjuvant chemotherapy to death from HGSC. Survival functions were 
estimated using the Kaplan-Meier method and the log-rank test was applied. 
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Results 
Response to chemotherapy in the study cohort  
Samples from a total of fifty-four patients receiving NACT and six patients who had 
surgery prior to chemotherapy were used in the experiments in this paper. 
Supplementary Table 3 summarizes the sample numbers used in each set of 
experiments. As described above, the response to chemotherapy was assessed in the 
interval debulking, IDS, biopsies using the CRS (18). CRS1 samples show minimal 
response to chemotherapy, CRS2,‘poor’ responders, have easily identifiable malignant 
cells in the omentum after NACT and CRS3, ‘good’ responders, usually show extensive 
regression-associated fibro-inflammatory changes with absent or minimal numbers of 
malignant cells (18). None of the IDS samples in our experiments, by chance and due to 
prevalence, scored as CRS1. ‘Good responder’ patients with samples scored as CRS3 
had significantly improved progression-free survival (p=0.002) and overall survival 
(p=0.03) compared to ‘poor responder’ patients whose biopsies scored as CRS2 
(Supplementary Figure 1).  
T cell density pre and post NACT 
From twenty-five of the HGSC patients described above, we obtained matched omental 
biopsies taken at pretreatment and at IDS. Using immunohistochemistry, the biopsies 
were stained for CD8+ T cells, CD45RO+ memory cells and Foxp3+T regulatory cells.  
Figure 1 and Supplementary Figure 2 show the cell density in malignant cell areas and 
adjacent stromal areas. Pretreatment, there was no difference in the density of cells 
positive for the above markers between CRS2 ‘poor’ and CRS3 ‘good’ responders. After 
NACT there were still marked infiltrates of CD8+ T cells and CD45RO+ memory cells in 
the stroma and again no difference between CRS2 or CRS3 biopsies. CD8+ T cells and 
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CD45RO+ memory cells in the malignant cell areas of CRS2 biopsies remained at high 
levels; in fact CD8+ cell density increased in approximately 50% of patients and the 
tumor:stroma ratio of CD8+ and CD45RO+ cells in individual patients was essentially 
unchanged pre and post chemotherapy in the CRS2 biopsies (Supplementary Figure 3).  
In contrast, there was a significant decline in the density of Foxp3+ cells in the stromal 
areas of the CRS3 ‘good’ responder biopsies after NACT (p=0.02) but there was no 
significant change in the CRS2 biopsies (Figure 1). As Foxp3 is a marker of 
immunosuppressive T regulatory cells, we next asked whether NACT increased T cell 
activation.  
Evidence for T cell activation after NACT 
We assessed the phenotype of the T cells in the HGSC omental metastases by flow 
cytometry analysis of tumor-infiltrating leukocytes from twenty-two of the HGSC 
biopsies. As it was not possible to obtain sufficient material for flow cytometry from 
diagnostic biopsies for pretreatment samples in these experiments, to assess 
pretreatment T cell phenotypes we used six samples obtained at primary debulking and 
two laparoscopic biopsies obtained before NACT. In agreement with the results in 
Figure 1, the percentage of CD3+ cells in the CD45+ leukocyte population did not 
change pre or post NACT, irrespective of response to chemotherapy (Figure 2A). 
Likewise there were no significant changes in CD8+, CD4+ T cells or CD4:CD8 ratio 
(Figure 2B-D). A subpopulation of the CD4+ T cells was CD25+ Foxp3+ suggesting they 
were T-regulatory cells. When comparing CRS2 and CRS3 patients we observed a 
decrease in the percentage of CD4+ T cells that were CD25+Foxp3+ in the CRS3 
biopsies (p=0.015, Mann-Whitney test) (Figure 2E), again supporting the results in 
Figure 1. The ratio of CD4+CD25+ Foxp3+ cells to CD4+CD25+Foxp3- cells also 
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decreased in post NACT CRS3 and CRS2 biopsies compared to pre-treatment, and the 
difference between CRS2 and CRS3 was significant (p=0.03, Mann-Whitney test) 
(Figure 2F). When applying a correction for multiple group comparison, the differences 
were not deemed significant (p=0.06 (Figure 2E) and p=0.09 (Figure 2F), Kruskal-Wallis 
test). 
We next studied the functional ability of the T cells in the biopsies to produce IFN-γ as a 
marker of T cell activation and anti-tumor response, and IL-10 as a marker of 
immunosuppression. Cells extracted from eleven HGSC omental samples, as well as 
peripheral blood mononuclear cells, PBMCs, from healthy control women (n=3-5), were 
stimulated in vitro and then stained for intracellular IFNγ and IL-10 (Figure 2G, H). A 
significantly higher proportion of omental CD4+ and CD8+ T cells were able to produce 
IFNγ compared to peripheral T cells from healthy controls. When compared to pre 
treatment biopsies, post NACT CRS3 patients had a significantly higher proportion of 
IFNγ+ CD4+ T cells (p=0.002, Figure 2G). No significant difference in the proportion of 
IL10 producing CD4+ and CD8+T cells was observed between pre and post NACT 
samples (Figure 2G, H).  
Gene set enrichment analysis of immune gene signatures pre and post NACT  
We extracted total RNA from twenty of the HGSC omental metastasis biopsies for which 
we had sufficient material and analysed gene expression by RNAseq. Nine samples 
were from CRS3 good responders post NACT and seven from CRS2 poor responders. 
For pre-treatment samples we used two biopsies from stage IIIC or IV HGSC patients 
undergoing primary debulking surgery and two biopsies obtained from patients before 
NACT as described for Figure 2. Gene set enrichment analysis (GSEA) was conducted 
Changes to immune cell phenotypes from both the adaptive and innate pathways were 
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seen when comparing CRS3 to CRS2 samples, and individually (CRS2 or CRS3) to Pre 
NACT samples. In particular changes associated with T-cell phenotype were found to 
have the highest significance (lowest FDR value). In agreement with the results in 
Figures 1 and 2, we found that the FOXP3-associated T regulatory cell gene signatures 
were differentially regulated in pre versus post NACT patients. FOXP3 regulated genes 
whose expression is decreased following differentiation to a T regulatory phenotype (25) 
were enriched in pretreatment versus both CRS2 and CRS3 post NACT biopsies 
(Figure 3A and B). We also observed an enrichment of this gene signature in CRS2 
poor responder biopsies compared to CRS3 biopsies (Figure 3C). 
Further GSEA analysis revealed an increase in expression of T-helper 1 (Th1)- 
associated genes after NACT in both poor (CRS2) and good (CRS3) responders 
(Figure 4A, 4B). The gene set used contained genes that were experimentally up-
regulated when naïve T-cells were activated to a Th1 phenotype in vitro (26). We also 
noted that the Th1 phenotype was enriched in CRS3 patients compared to CRS2 
(Figure 4C). Meta analysis of TCGA data has identified GZMA (encoding granzyme A) 
and PRF1 (encoding perforin 1) as specifically co-expressed by cytotoxic T-cells (12). 
We compared gene expression levels for both markers within our data set (Figure 4D-
F). There was a tendency for both genes to be upregulated in the post NACT versus 
pretreatment samples and the difference with PRF1 was significant p=0.03 (Figure 
4D,E). The geometric mean of both genes (Figure 4F) again showed a tendency 
towards upregulation post-NACT. These experiments suggest that NACT reduced T 
regulatory cell activity in HGSC metastases while increasing T cell activation and Th1 
responses and these effects were most profound in the CRS3 good responder patients. 
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We next asked if the potential for efficient host anti-tumor immune responses was 
influenced by immune checkpoint molecules. 
The effect of NACT on immune checkpoint molecules  
More than 60% of CD4+ and CD8+ T cells in omental metastases from six pre and 
sixteen post NACT patients expressed the immune checkpoint molecule programmed 
cell death-1 (PD-1) as assessed by flow cytometry (Figure 5A and B). Between 15 and 
30% of the CD4+ cells and 5 to 10% of the CD8+ cells expressed cytotoxic T-
lymphocyte-associated protein 4, CTLA4, in twenty-two biopsies (Figure 5C and D) and 
most of the CTLA4+ T cells co-expressed PD-1 (Figure 5E and F).  
Immunohistochemistry staining showed that the PD-1 ligand PD-L1 was frequently 
associated with the immune cell compartment of the HGSC tumor microenvironment. 
Using an antibody developed for anti-PD-L1 clinical trials (clone SP142) and a scoring 
method on immune cells (20) we found that PD-L1 protein was significantly increased in 
post NACT compared to pre NACT biopsies irrespective of response to treatment in 
paired pre- and post NACT biopsies of twenty-six patients (p=0.03, Figure 5F, G and 
Supplementary Figure 4). Hence, potential beneficial effects of chemotherapy in 
stimulating T cell activation might be impaired by the high expression of immune 
checkpoint molecules. 
Plasma levels of cytokines 
Cancer-related inflammatory pathways can also contribute to the immune suppressive 
tumor microenvironment (27) and ovarian cancers have complex tumor-promoting 
inflammatory cytokine networks (28) that can be reflected by increases in systemic 
cytokine levels (29). We measured key cytokines implicated in tumor-promoting 
inflammation, as well as T cell activation and immune suppression, in forty-six matched 
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pre and post NACT plasma samples from twenty-three patients. Levels of three major 
inflammatory cytokines with potential tumor-promoting activity, TNF, IL-8 and IL-6, 
significantly decreased after NACT (p=0.0008, p=0.001 and p=0.0006, respectively, 
Figure 6A-C). All plasma levels were elevated pre-treatment but post NACT levels were 
not statistically different from values obtained from twenty-two healthy females. There 
were no differences between patients whose samples were scored CRS2 and CRS3.  
In contrast, plasma IFNγ was increased in post treatment patients compared to healthy 
controls (p=0.005) with a trend towards an increase post-treatment versus pre-treatment 
(Figure 6D). Pre-treatment patient plasma IL-10 levels were significantly higher 
compared to controls before NACT (p=0.04) and decreased after NACT (p<0.001 
(Figure 6E). IL-17 levels were significantly elevated in HGSC patients compared to 
controls (p=0.006) and remained elevated after NACT (p=0.02, Figure 6F).  
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Discussion  
As well as in malignant melanoma, there have been some encouraging responses to 
immune checkpoint inhibitor therapy in patients with difficult-to treat metastatic solid 
cancers such as non-small cell lung cancer (30), bladder cancer (20) and ovarian 
cancer (13). However many patients show no benefit, not all cancer types respond and 
most trials are conducted after multiple treatments and with drug-resistant disease. The 
hypothesis of our study was that immunotherapies such as immune checkpoint 
blockade may result in enhanced clinical benefit if given after or during first line 
chemotherapy. The NACT protocols used for many patients with stage IIIC and stage IV 
HGSC gave us an opportunity to investigate this in a clinical setting. 
We believe that this is the first in-depth analysis of the effects of first-line chemotherapy 
on a human metastatic tumor microenvironment. We demonstrate that NACT induces 
activation of CD4+ T-cells and that CD8+ T cells and CD45RO+ memory cells are 
present in omental metastases after NACT. By incorporating a recently developed 
prognostically significant histological score (18) we show that omental metastases 
biopsies from patients with good response (CRS3) to NACT have more pronounced T-
cell activation and reduced T regulatory cell infiltration compared to poor responders 
(CRS2). Importantly, even those patients who had a poor response to three cycles of 
platinum-based chemotherapy had high densities of CD8+ T cells and CD45RO+ 
memory cells and their ability to produce IFNγ was preserved. Moreover, increased 
levels of transcripts coding for cytotoxic markers post-NACT suggested chemotherapy 
might enhance the cytotoxicity of immune effector cells, such as CD8+ T cells and NK 
cells towards the tumor.  These local changes were accompanied by a decline, usually 
back to healthy control values, in systemic levels of cytokines implicated in cancer-
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related inflammation in all patients. The potential enhancement of host anti-tumor 
immune response and reduction in mediators of cancer-related inflammation was 
tempered by the fact that levels of the immune-checkpoint molecules PD-1 and CTLA4 
on CD4+ and CD8+ T-cells remained high after NACT. Levels of PD-L1 ligand on tumor-
infiltrating immune cells were significantly increased. The fact that the immune 
checkpoint targets are present or increased after NACT, in the presence of significant 
densities of CD8+ T cells and memory cells provides a rationale for cancer 
immunotherapy, especially immune checkpoint blockade, in the HGSC first line setting 
at this early time point. The presence or absence of T-cells in solid tumors is a key 
limiting factor for cancer immunotherapy (31) and the presence of CD8+ T cells at the 
invasive margin was predictive of response to anti PD-1 treatment in malignant 
melanoma (32).  
There is already some evidence that prior chemotherapy enhances the effect of 
immunotherapy. Successful responses to adoptive therapy with CAR T cells, TCR T 
cells, and TILs are regularly seen in cancer patients who have become chemotherapy-
resistant. In terms of ovarian cancer, there were responses to interleukin-2 
immunotherapy in patients who had become resistant to platinum therapy (33), while in 
a first-line study chemotherapy plus IFNγ 1-b immunotherapy showed a decreased OS 
compared to chemotherapy alone (34). This highlights the need for careful monitoring of 
patients during combination chemotherapy. 
The relative contribution of platinum versus taxane to the immunostimulatory effects 
seen in our study is an open question because almost all patients received the 
combination therapy. Experimental studies suggest that cisplatin does not induce 
immunogenic cell death (ICD) (35) but carboplatin and docetaxel produce partial 
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features of ICD (36). Chemotherapy can also activate the host immune system by 
several other mechanisms (37) such as increased presentation of neo-antigens. 
Chemotherapy before immunotherapy is of particular interest since efficacy of PD-1 
blockade has recently been shown to correlate with neoantigen burden in non-small cell 
lung cancer (38). 
In ovarian cancer there are conflicting results relating to the prognostic impact of T 
regulatory cells (39,40). Our data obtained at transcriptional, protein and cellular level 
show a reduced T regulatory cell signature and density after NACT is most apparent in 
biopsies of tumors classified as CRS3 good responders, providing evidence for a link 
between chemotherapy efficiency and Treg density. In addition to reduced Tregs after 
NACT in good responders we have observed by flow cytometry a shift of the Foxp3- 
population towards increased CD25 expression, again most pronounced in good 
responders. This population has been shown to have an ‘exhausted’ phenotype that 
could effectively been reversed using an anti-PD-1 monoclonal antibody (41). We 
suggest that blocking the PD-1/PD-L1 axis is a way to inhibit T regulatory cell function 
and enhance the antitumor-effectiveness of the CD4+CD25+ T cells. Future work in 
larger cohorts may reveal insights into functionally different subsets of T regulatory cells 
with potentially different prognostic and predictive value (42) (43).  
There is much evidence that cancer-related inflammation is also tumor-promoting (44) 
although clinical trials that target inflammatory mediators or cells are not as advanced 
as some other immunotherapy approaches (27) (34). As the adaptive immune response 
is heavily dependent on innate immunity, inhibiting some of the tumor-promoting 
immunosuppressive actions of the innate immune system might enhance the potential 
of immunotherapies that activate a nascent antitumor response. It is therefore 
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encouraging that NACT had a significant impact on systemic levels of three key 
inflammatory cytokines in our study. TNF and IL-6 are major players in the complex 
cytokine networks that drive tumor progression in ovarian cancer (28,29,45). Elevated 
IL-6 produced by malignant cells was a cause of paraneoplastic thrombocytosis in 
HGSC patients (29) and plasma IL-8 correlated with tumor burden and treatment 
response across a range of human and experimental cancers (46). The observation that 
all three cytokines decrease to normal plasma levels after NACT further suggests that 
this is a favorable time to introduce immunotherapy, taken with the finding of an 
increase in the Th1 cytokine IFNγ in the patient plasma. 
In summary, we have been able to study the human tumor microenvironment at the 
transcriptomic, proteomic and cellular level at a key site of cancer dissemination and 
under conditions that reflect current practice of patient care – the disease at diagnosis 
and after NACT. Our results suggest that NACT opens a window of opportunity for 
immunotherapies such as immune checkpoint blockade for patients with different levels 
of response to chemotherapy. We conclude that incorporation of immunotherapies into 
post chemotherapy treatment options could be of benefit for prolonged disease control 
in patients with advanced HGSC and, if confirmed, in patients with other cancer types. 
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Figure Legends: 
Figure 1. T cell density and location in matched pre- and post-treatment omental 
biopsies 
Amount and localization of CD8+ T-cells, CD45RO+ memory cells and Foxp3+ cells in 
omental metastasis in fifty matched pre and post chemotherapy peritoneal biopsies from 
twenty-five patients.  
Analysis of cell amount pre- to post NACT based on a 5-tier score in tumor and stroma. 
Intratumoral cells post NACT in CRS3 good responders are ‘not applicable’ since no 
large tumor islets are left in the omentum after NACT in these patients. Note that all 
CRS2 biopsies post NACT were positive for intra-tumoral and intra-stromal CD8+ and 
CD45RO+ cells, in many samples increased compared to pre chemotherapy. Foxp3+ T 
regulatory cells do not increase in tumor and stroma of CRS2 biopsies and decrease 
significantly in stroma of CRS3 biopsies (* = p<0.05).  
 
Figure 2. Effect of NACT on the T cell populations in omental metastases 
(A to D) Flow cytometry analysis of the percentage of CD3+CD4+ and CD3+CD8+ T cells 
in omental metastases from six pre and sixteen post-treatment patients according to 
response. (E) The percentage of CD4+CD25+Foxp3+ T regulatory cells in omental 
metastases of six pre and sixteen post-NACT patients was analyzed by flow cytometry. 
(F) Shows the ratio of CD4+CD25+Foxp3+ Tregs to CD4+CD25+Foxp3- T cells. (G and 
H) Cells extracted from eleven omental metastases (3 pre-treatment, 5 post-NACT 
CRS3 good responders and 3 post-NACT CRS2 poor responders) and healthy blood 
(n=3 to 5) were re-stimulated in culture with 50ng/ml PMA, 1µg/ml Ionomycin and 
10µg/ml Brefeldin A for 5 hours and stained for the presence of intracellular IFNγ and 
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IL10 in CD4+ and CD8+ T cells. Not indicated in the figures: The percentage of 
CD4+IFNγ+ and CD8+IFNγ+ cells was significantly higher in pre and post treatment 
omental metastases compared to control blood (p< 0.001); the percentage of CD4+IL10+ 
and CD8+IL10+ cells was significantly higher in metastases from CRS3 patients 
compared to control blood (p<0.05). All other significant results indicated with * = p<0.05 
and ** = p<0.01.   
 
Figure 3. Gene expression analysis of Treg signature pre and post NACT  
GSEA analysis of twenty samples using a set of genes down regulated on conversion of 
a naïve T cell to a Treg phenotype compared against a FOXP3 mutant T-cell line (25). 
Red squares indicate genes of the core enrichment, shown in the corresponding 
heatmap. A) Pre vs Post CRS3 good responders, FDR < 0.0001, B) Pre vs Post CRS2 
poor responders, FDR <0.0001 and C) Post CRS3 vs Post CRS2, FDR = 0.009.  
 
Figure 4. Gene expression analysis of T-cell responses to NACT 
(A-B) GSEA Th1 signature generated from naïve T-cells that have been activated to a 
Th1 phenotype in vitro (26) is enriched after NACT in (A) CRS2 poor responders (FDR 
= 0.02) and (B) CRS3 good responders (FDR = 0.004) compared to pre-treatment and 
(C) the same signature compared between good and poor responders to NACT (FDR = 
0.014). Red squares indicate genes of the core enrichment, shown in the corresponding 
heatmap. D) and E) transcripts per million (TPM) of PRF1 and GZMA expression 
between Pre and Post NACT samples, and F) the geometric mean of PRF1 and GZMA 
expression compared between Pre and Post NACT samples. (* = p<0.05)  
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Figure 5. Expression of checkpoint molecules in omental metastasis before 
treatment and according to response to chemotherapy 
(A to F) Expression of PD-1 and CTLA4 on CD4+ and CD8+ T cells assessed on twenty-
two samples separated into pre-treatment and post NACT according to CRS scores. (G) 
Examples of positive staining for PD-L1 before and after NACT (IHC, antibody clone 
SP142), (H) Analysis of IHC staining for PD-L1 positive immune cells in fifty-two paired 
samples before and after NACT. (* = p<0.05) 
 
Figure 6. Systemic cytokine levels before and after neoadjuvant chemotherapy. 
(A to F) Systemic levels of TNF (A), IL-8 (B), IL-6 (C), IFNγ (D), IL-10 (E) and IL17 (F) in 
fourty-six paired pre and post NACT plasma samples of twenty-three patients and of 
twenty-two healthy female controls (IL-17: ten controls) measured by 
electrochemoluminescence multiplex assays. (* = p<0.05; ** = p<0.01). 
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